Holen Sie sich die Stockscreener-App
2.49
1.69%
-0.02
Schlusskurs vom Vortag:
$2.51
Offen:
$2.44
24-Stunden-Volumen:
85,556
Relative Volume:
0.48
Marktkapitalisierung:
$4.57M
Einnahmen:
$6.59M
Nettoeinkommen (Verlust:
$-18.12M
KGV:
-0.2632
EPS:
-9.4605
Netto-Cashflow:
$-11.45M
1W Leistung:
-26.45%
1M Leistung:
-27.63%
6M Leistung:
-30.60%
1J Leistung:
-88.41%
1-Tages-Spanne:
$2.34
$2.529
1-Wochen-Bereich:
$2.10
$3.34
52-Wochen-Spanne:
$1.50
$36.65
Hcw Biologics Inc Stock (HCWB) Company Profile
Firmenname
Hcw Biologics Inc
Sektor
Branche
Telefon
954-842-2024
Adresse
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
2.49 | 4.61M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.05 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.68 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.07 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hcw Biologics Inc Aktie (HCWB) Neueste Nachrichten
HCWB Looks 92.8% Undervalued on GF Value™ Despite Financial Distress - GuruFocus
HCW Biologics signs global HCW11-006 distribution deal - TipRanks
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent - Yahoo Finance
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com Canada
HCWB Stock In Focus As Holders File To Sell 1.24M Shares - timothysykes.com
HCWB Stock Faces Pressure As Shareholders Plan Secondary Sale - StocksToTrade
HCW Biologics signs distribution deal with Akron Biotech - Investing.com
HCW Biologics Entered an Exclusive Distribution Agreement - GlobeNewswire
symbol__ Stock Quote Price and Forecast - cnn.com
Hcw Biologics Stock Price Forecast. Should You Buy HCWB? - StockInvest.us
HCW Biologics (NASDAQ: HCWB) asks investors to vote on more equity than its current share count - Stock Titan
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Investing News Network
HCWB Looks 90.0% Undervalued on GF Value™ - GuruFocus
HCW Biologics Strengthens U.S. Patent Estate for Its Lead - GlobeNewswire
HCW Biologics Inc. SEC Filing (Sep 1, 2026) - Stock Titan
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceBackspread Trade - siam.in
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Canada
Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells - Stock Titan
HCW (HCWB) Financial Update: The EPS Result Is Above Expectation in the Latest Reading; Investor Response: The Share Price Adds 2.83% on the DayEarnings Call Transcript - vinanet.vn
HCW (HCWB): Finishes 2.83% Up at $2.18 in the Latest Reading; Range Check: Price Remains Between $2.07 Support and $2.29 ResistanceBPI Bull Confirmed - vinanet.vn
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - vinanet.vn
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
HCW Biologics (HCWB) posts higher 2026 revenue but flags going-concern risk - Stock Titan
HCW Biologics Reports Second Quarter 2026 Financial Results and Updates HCW9302 Alopecia Areata Program, HCW11-018b Development and Financing Activities - Quiver Quantitative
HCW Biologics trial: 3 alopecia patients cut SALT scores 25%+ - Stock Titan
HCWB Q1 2026 Earnings: Surprise EPS of $2.22 vs. Expected Loss, Yet Shares Slip 3.06%Consensus Miss Rate - Vinanet
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HCWB Q1 2026 Earnings: EPS of $2.22 Surges Past Loss EstimatesEarnings Power Value - vinanet.vn
HCW Biologics (HCWB) completes $1.6M exempt equity and warrant sale - Stock Titan
HCW Biologics | D: Filing D - Moomoo
HCWB Q2'26 Earnings: EPS estimate is (1.98) USD - TradingView
Price to earnings forward of HCW Biologics Inc. – NASDAQ:HCWB - TradingView
HCW Biologics (HCWB) director buys stock, entitled to new warrants - Stock Titan
HCW Biologics Announces $1.6 Million Private Placement Financing - The Globe and Mail
HCWB Q1 2026 Earnings: Surprising Profitability Driven by Non-Operating GainsHigh Growth Earnings - vinanet.vn
HCW Biologics Raises $1.6 Million in Private Placement; Units Priced at $2.585 - TradingView
HCW Biologics Prices $1.6 Million Private Placement Offering - marketscreener.com
HCWB Looks 94.1% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
HCW Biologics prices $1.6M private placement offering By Investing.com - Investing.com Canada
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering - GlobeNewswire
HCW Biologics prices $1.6M private placement with insiders - Investing.com
HCWB|HCW Biologics Inc|Price:2.640|Chg%:+0.140 - TradingKey
HCW Biologics Inc (HCWB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Finanzdaten der Hcw Biologics Inc-Aktie (HCWB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hcw Biologics Inc-Aktie (HCWB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Flowers Lee | SVP of Business Development |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
8,691 |
| GARRETT SCOTT T | Director |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
41,644 |
| Wong Hing C | Chief Executive Officer |
May 22 '26 |
Buy |
1.41 |
113,879 |
160,000 |
615,790 |
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):